Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 21

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 21
---
 parties to use or disclose our confidential information, such as trade secrets. Despite these contractual provisions,
the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by potential
competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements.
Given that our proprietary position is based, in part, on our know-how and trade secrets, discovery by a third party of our trade secrets
or other unauthorized use or disclosure would impair our intellectual property rights and protections in our drug candidates.

In addition, these agreements
typically restrict the ability of our collaborators, advisors, employees and consultants to publish data potentially relating to our trade
secrets. Our academic collaborators typically have rights to publish data, provided that we are notified in advance and may delay publication
for a specified time in order to secure our intellectual property rights arising from the collaboration. In other cases, publication rights
are controlled exclusively by us. In other cases, we may share these rights with other parties. Despite our efforts to protect our trade
secrets, our competitors may discover our trade secrets, either through breach of these agreements, independent development or publication
of information including our trade secrets in cases where we do not have proprietary or otherwise protected rights at the time of publication.

Obtaining and maintaining our patent protection
depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent
agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance fees,
renewal fees, annuity fees and various other governmental fees on patents and applications are required to be paid to the United State
Patent and Trademark Office and other governmental patent agencies outside of the United States in several stages over the lifetime of
the patents and applications. The USPTO and various corresponding governmental patent agencies outside of the United States require compliance
with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and after a patent
has issued. There are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting
in partial or complete loss of patent rights in the relevant jurisdiction.

We may become involved in lawsuits to protect
and defend our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.

Competitors may infringe our
patents or other intellectual property and we may inadvertently infringe the patent or intellectual property of others. To counter infringement